# A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis

> **NCT01094262** · PHASE2 · TERMINATED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 196 (actual)

## Conditions studied

- Osteoarthritis
- Osteoarthritis, Knee
- Pain
- Arthralgia
- Joint Pain

## Interventions

- **DRUG:** Oxycodone CR (standard pain medication)
- **DRUG:** JNJ-42160443
- **DRUG:** JNJ-42160443
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01094262
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-04-20
- **Primary completion:** 2011-07-01
- **Final completion:** 2011-07-01
- **Target enrollment:** 196 (ACTUAL)
- **Why stopped:** Logistic reasons associated with the FDA-imposed clinical hold.
- **Last updated:** 2020-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01094262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01094262, "A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01094262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*